Last reviewed · How we verify
mOPV2 at 6 and 10 weeks of age
mOPV2 at 6 and 10 weeks of age is a Biologic drug developed by Centers for Disease Control and Prevention. It is currently FDA-approved.
At a glance
| Generic name | mOPV2 at 6 and 10 weeks of age |
|---|---|
| Sponsor | Centers for Disease Control and Prevention |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Immunogenicity of Monovalent Type 2 Oral Poliovirus Vaccine (PHASE4)
- Safety and Immunogenicity of 1 or 2 Doses of IPV in Latin American Infants Primed With Bivalent OPV Vaccine (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- mOPV2 at 6 and 10 weeks of age CI brief — competitive landscape report
- mOPV2 at 6 and 10 weeks of age updates RSS · CI watch RSS
- Centers for Disease Control and Prevention portfolio CI
Frequently asked questions about mOPV2 at 6 and 10 weeks of age
What is mOPV2 at 6 and 10 weeks of age?
mOPV2 at 6 and 10 weeks of age is a Biologic drug developed by Centers for Disease Control and Prevention.
Who makes mOPV2 at 6 and 10 weeks of age?
mOPV2 at 6 and 10 weeks of age is developed and marketed by Centers for Disease Control and Prevention (see full Centers for Disease Control and Prevention pipeline at /company/centers-for-disease-control-and-prevention).
What development phase is mOPV2 at 6 and 10 weeks of age in?
mOPV2 at 6 and 10 weeks of age is FDA-approved (marketed).